Analyst Ratings For Akari Therapeutics (NASDAQ:AKTX)
Today, B. Riley initiated coverage on Akari Therapeutics (NASDAQ:AKTX) with a Neutral with a price target of $3.00.
Some recent analyst ratings include
- 2/8/2018-B. Riley initiated coverage with a Neutral rating.
- 9/22/2017-Canaccord Genuity Reiterated Rating of Buy.
- 9/22/2017-William Blair Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 9/17/2017-Chardan Capital Reiterated Rating of Neutral.
Recent Insider Trading Activity For Akari Therapeutics (NASDAQ:AKTX)
Akari Therapeutics (NASDAQ:AKTX) has insider ownership of 61.80% and institutional ownership of 21.05%.
- On 9/18/2015 Mark S Cohen, Director, bought 1,055,600 with an average share price of $0.19 per share and the total transaction amounting to $200,564.00.
- On 4/15/2014 Sabby Management, Llc, Major Shareholder, bought 20,100 with an average share price of $5.03 per share and the total transaction amounting to $101,103.00.
- On 4/11/2014 Sabby Management, Llc, Major Shareholder, bought 2,575 with an average share price of $5.35 per share and the total transaction amounting to $13,776.25.
- On 4/8/2014 Sabby Management, Llc, Major Shareholder, bought 68,404 with an average share price of $5.59 per share and the total transaction amounting to $382,378.36.
- On 4/2/2014 Sabby Management, Llc, Major Shareholder, bought 28,207 with an average share price of $6.22 per share and the total transaction amounting to $175,447.54.
- On 3/27/2014 Sabby Management, Llc, Major Shareholder, bought 16,203 with an average share price of $6.66 per share and the total transaction amounting to $107,911.98.
- On 3/24/2014 Sabby Management, Llc, Major Shareholder, bought 11,100 with an average share price of $6.83 per share and the total transaction amounting to $75,813.00.
Recent Trading Activity for Akari Therapeutics (NASDAQ:AKTX)
Shares of Akari Therapeutics closed the previous trading session at 2.28 up +0.09 4.11% with 2.200000047683716 shares trading hands.
